Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients

American Journal of Nephrology

Volumn 26, Issue 5, 2006, Pages 423-429

  Cozzolino, Mario ^a,c   Galassi, Andrea ^a   Biondi, Maria Luisa ^a   Turri, Olivia ^a   Papagni, Sergio ^b   Mongelli, Nicola ^b   Civita, Luigi ^b   Gallieni, Maurizio ^a   Brancaccio, Diego ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CBH   (Italy)

^c SAN PAOLO HOSPITAL   (Italy)

Author keywords

Chronic kidney disease; Fetuin A; Hemodialysis; Vascular calcification

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FETUIN; FETUIN A;

ABDOMINAL AORTA; ADULT; AGED; AORTA VALVE; ARTICLE; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HEART CALCIFICATION; HEMODIALYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CALCINOSIS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33845797007     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095782     Document Type: Article

References (26)

1. Foley RN, Parfrey PS: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S112-S119.
2. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906.
3. Longenecker JC, Coresh J, Powe NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 2002;13:1918-1927.
4. London GM: Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003;14:S305-S309.
5. Guérin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
6. Blacher J, Guérin AP, Pannier B, et al: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-2439.
7. Blacher J, Guérin AP, Pannier B, et al: Arterial calcifications, arterial stiffness and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
8. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001;12:2511-2516.
9. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959-2964.
10. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-436.
11. 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. J Biol Chem 1996;271:20789-20796.
12. 2-Heremans-Schmid glycoprotein/fetuin A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366.
13. Ketteler M, Bongartz P, Westenfeld R, et al: Association of low fetuin-A concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-833.
14. Zimmermann J, Herrlinger S, Pruy A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
15. Menon V, Greene T, Wang X, et al: C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005;68:766-772.
16. Zoccali C, Tripepi G, Mallamaci F: Predictors of cardiovascular death in ESRD. Semin Nephrol 2005;25:358-362.
17. Honda H, Qureshi AR, Heimburger O, et al: Serum albumin, C-reactive protein, interleukin-6, and fetuin as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139-148.
18. Cases A: New cardiovascular risk factors and chronic kidney disease. Hypertrophy of the left ventricle. Atrial fibrillation. Smoking. Obesity. Emerging cardiovascular risk (in Spanish). Nefrologia 2004;24(suppl 6):62-72.
19. Moe SM, Reslerova M, Ketteler M, et al: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;67:2295-2304.
20. Mehrotra R, Westenfeld R, Christenson P, et al: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005;67:1070-1077.
21. Stenvinkel P, Wang K, Qureshi AR, et al: Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-2392.
22. Hermans MMH, Brandenburg V, Ketteler M, et al: Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2005;21:1293-1299.
23. Goodman WG, Goldin J, Kuizon BD, et al: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
24. 2-HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-1129.
25. Kushner I, Broder ML, Karp D: Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest 1978;61:235-242.
26. Tsirpanlis G, Bagos P, Ioannou T, et al: The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:150-157.